| PLK4 Protein |
|---|
| Protein Name | Polo-Like Kinase 4 |
| Gene | [PLK4](/genes/plk4) |
| UniProt ID | [Q9Y5A9](https://www.uniprot.org/uniprot/Q9Y5A9) |
| Alternative Names | Sak, Snk, Serine/threonine-protein kinase PLK4 |
| Molecular Weight | ~97 kDa |
| Subcellular Localization | Centrosome, nucleus |
| Protein Family | Polo-like kinase family |
| Enzyme Classification | EC 2.7.11.1 (Protein kinase) |
PLK4 (Polo-Like Kinase 4) is a serine/threonine protein kinase belonging to the Polo-like kinase family. Originally identified as a key regulator of centriole duplication and cell division, PLK4 has more recently been implicated in neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis (ALS). PLK4 is unique among Polo-like kinases in its role in governing centrosome biology and its involvement in neuronal survival pathways.
¶ Structure and Function
¶ Kinase Domain Architecture
PLK4 contains several functional domains:
- N-terminal kinase domain: Catalytic serine/threonine kinase activity
- Polo-box domains (PBD): Two polo-box motifs that recognize phosphorylated substrates
- Leucine zipper: Mediates protein-protein interactions
- Dynein light chain binding site: Enables microtubule-based transport
PLK4 phosphorylates key substrates involved in:
- Centriole duplication: STIL, SAS6, and CPAP
- Cell cycle regulation: CDK1/Cyclin B substrates
- DNA damage response: ATR/Chk1 pathway components
- Microtubule organization: Pericentriolar material proteins
PLK4 dysregulation in AD relates to:
- Tau phosphorylation: PLK4 can phosphorylate tau at disease-relevant sites
- Cell cycle re-entry: Neuronal cell cycle abnormalities in AD involve PLK4
- Centrosome dysfunction: Abnormal centrosomes in AD neurons
- DNA damage response: PLK4 activation in stressed neurons
In PD, PLK4 participates in:
- Alpha-synuclein phosphorylation: PLK4 can phosphorylate alpha-synuclein at Ser129
- Dopaminergic neuron survival: PLK4 is protective in substantia nigra neurons
- Mitophagy: PLK4 involvement in mitochondrial quality control
- Stress response: PLK4 activation in cellular stress models
In ALS, PLK4 has been studied for:
- TDP-43 pathology: PLK4 may phosphorylate TDP-43
- Motor neuron survival: PLK4 activity affects motor neuron viability
- Protein aggregation: Interactions with aggregation-prone proteins
PLK4 contributes to neurodegeneration through:
- Aberrant cell cycle activation: PLK4 promotes inappropriate neuronal cell cycle re-entry
- Centrosome abnormalities: Disrupted centrosome function affects neuronal polarity
- Proteostasis disruption: PLK4 affects protein quality control systems
- Oxidative stress: PLK4 responds to and modulates oxidative stress
PLK4 is a potential drug target:
- ATP-competitive inhibitors: Small molecules targeting the kinase domain
- Allosteric modulators: Compounds targeting regulatory domains
- Substrate-directed inhibitors: Molecules blocking PLK4-substrate interactions
PLK4 activity may serve as:
- Disease progression marker: PLK4 levels correlate with disease stage
- Therapeutic response indicator: Treatment effects on PLK4 activity
- Risk stratification: PLK4 genetic variants and disease risk
PLK4 polymorphisms have been studied in:
- Neurodegenerative disease risk: Some associations reported
- Cancer predisposition: Biallelic mutations cause microcephaly
- Developmental disorders: PLK4 haploinsufficiency affects brain development
No PLK4-targeted therapies are currently in clinical trials for neurodegenerative diseases, though:
- Preclinical studies: PLK4 inhibitors show promise in models
- Repurposing potential: Existing oncology drugs may be repurposed
- Cell Cycle in Neurodegeneration
- Tau Phosphorylation Pathways
- Centrosome Dysfunction in Neurodegeneration
- Alpha-Synuclein Phosphorylation